Abstract: A device including an activated p-type layer comprising a III-Nitride based Mg-doped layer grown by vapor phase deposition or a growth method different from MBE. The p-type layer is activated through a sidewall of the p-type layer after the removal of defects from the sidewall thereby increasing a hole concentration in the p-type layer. In one or more examples, the device includes an active region between a first n-type layer and the p-type layer; a second n-type layer on the p-type layer; and a tunnel junction between the second n-type layer and the p-type layer, and the activated p-type layer has a hole concentration characterized by a current density of at least 100 Amps per centimeter square flowing between the first n-type layer and the second n-type layer in response to a voltage of 4 volts or less applied across the first n-type layer and the second n-type layer.

Abstract: Systems and methods for utilizing a small form-factor, wirelessly powered transceiver are disclosed. In one embodiment, a wireless powered transceiver includes a receive antenna configured to receive a receive signal, a transmit antenna configured to transmit a transmit signal, a power harvesting system including a rectifier circuit configured convert radio frequency energy from the receive signal into DC (direct current) voltage, and a power management unit (PMU) configured to set the operating mode and biasing condition of the receive and transmit circuitry blocks and provide DC voltage from the receive circuitry block to the transmit circuitry block to maintain a minimum voltage, a receiver circuitry block configured to provide energy from the receive signal to the power harvesting system, and a transmitter circuitry block including a data modulator circuit, the data modulator circuit configured to generate the transmit signal using DC voltage received from the power management unit.

Abstract: The present disclosure relates to the use of recombinant proteins for inducing epigenetic modifications at specific loci, as well as to methods of using these recombinant proteins for modulating the expression of genes in plants.

Abstract: A multi-phase hybrid power converter architecture which provides high efficiency, high power density and high conversion ratios for non-isolated DC to DC power conversion. Hybrid converters are described in which a switched-capacitor network is interoperably merged with a switched-inductor network having multiple inductors, resulting in a circuit with reduced component count and in which soft-charging of the capacitors is performed. Multi-phase switching is utilized and includes a freewheeling state for output voltage regulation in which inductor current ramps down. The SC converter can be configured to provide various conversion ratios, such as 4-to-1, 6-to-1 and 8-to-1, and optimized for the needs of specific application.

Abstract: A smart retail product shelf liner called ‘MOOCA’ to detect product loads on its surface. The liner preferably has an origami like structure whose properties (e.g., angles, unit size, material) are adjusted to make the liner configurable for different sizes, load ranges, and product packaging. The smart liner is well suited for autonomous checkout systems. MOOCA is an origami-inspired low-cost configurable surface structure having conductive threads and copper wires integrated into the origami structure to detect and recognize product loads and thus to detect when products are either picked-up, or put-down, upon the smart MOOCA liner of the shelf.

Abstract: A Photonic molecule may include a first ring resonator that is tunable by a first piezoelectric actuator. A Photonic molecule may include a second ring resonator that is tunable by a second piezoelectric actuator, wherein the second ring resonator optically coupled to the first ring resonator. A Photonic molecule may include a third ring resonator that is tunable by a third piezoelectric actuator, wherein the third ring resonator is optically coupled to the first ring resonator and the second ring resonator. A Photonic molecule may include a waveguide optically coupled to the first ring resonator.

Abstract: A method for abnormality detection in an energy unit includes passively detecting an abnormality in an energy unit by detecting electromagnetic radiation generated by the abnormality, the energy unit comprising at least one of an electrical energy unit and an electrochemical energy unit. A method for detecting an abnormality in an energy unit includes (a) applying a signal to the energy unit, (b) performing a plurality of measurements, at a respective plurality of different locations within the energy unit, of a response of the energy unit to the signal, and (c) processing the plurality of measurements to identify the abnormality.

Abstract: Opsin proteins are GPCRs known for light perception. Here it is shown that these receptors are also expressed in chemosensory cells and function as chemosensory receptors activated by a range of molecules, including tastants such as theobromine, for which a receptor has not previously been known. Provided are novel assay systems for assessing chemosensory opsin activation by chemical ligands. By these assays, novel ligands of chemosensory opsins may be identified, the chemosensory properties of molecules may be evaluated; and the modulation of chemosensory properties by modifications or modulators may be tested.

Abstract: Candidate cancer antigens are identified using transposable elements. Differential expression levels are determined for proteins using baseline expression levels (using measurements of healthy tissue) and tumor expression levels (using measurements of tumor tissue). Protein(s) having a differential expression level greater than a threshold are selected. Cancer vaccine(s) are generated for the selected cancer antigens (s). Particular cancer vaccine(s) are selected for a patient based on differential expression levels for proteins using baseline expression levels of the patient and tumor expression levels of the patient. A vaccine for protein(s) having a differential expression level greater than a threshold can be selected. A microarray can be used for the measurements of the patient. A first array of probes can hybridize to RNA from transposable elements. A second array of probes can hybridize to RNA of different MHC haplotypes. A third array of probes can hybridize to RNA of different APOBEC genotypes.

Abstract: The invention relates to gene therapies using viral vectors. The invention provides, for the first time, packaging cells that comprise enhanced Fc receptor expression (e.g. CD16, CD32, or CD64) to generate gene therapy viruses that evade antibody-dependent inactivation (ADI) or complement-dependent inactivation (CDI). The invention also provides gene therapy viruses with the enhanced Fc receptors displayed on their viral envelope.

Abstract: A drug delivery for treating renal cancer, and in particular, clear cell renal carcinoma is provides. The drug delivery system includes a plurality of nanoparticles wherein each nanoparticle includes CD70-targeting peptides conjugated thereto and anti-HIF2? siRNAs conjugated thereto. A method for treating renal cancer is also provided.

Abstract: Recombinant proteins comprising a non-canonical amino acid with high yield and high fidelity are made by expressing the protein in an engineered Vibrio natriegens strain containing an orthogonal translation system comprising an orthogonal aminoacyl tRNA synthetase that charges the non-canonical amino acid onto the orthogonal cognate tRNA.

Abstract: Described herein are methods for characterizing the age of an insect fecal pellet, where the method can comprise: (1) obtaining insect fecal pellet material to be tested; (2) exposing the pellet material to an H2O2 solution; and (3) detecting the presence of generated oxygen, where the amount of oxygen generated is inversely proportional to the age of the insect pellet. Also described are kits for carrying out the method.

Abstract: Provided are compositions and methods that include one or more of: (1) a Class 2 CRISPR/Cas effector protein, a nucleic acid encoding the effector protein, and/or a modified host cell comprising the effector protein (and/or a nucleic acid encoding the same); (2) a CRISPR/Cas guide RNA that binds to and provides sequence specificity to the Class 2 CRISPR/Cas effector protein, a nucleic acid encoding the CRISPR/Cas guide RNA, and/or a modified host cell comprising the CRISPR/Cas guide RNA (and/or a nucleic acid encoding the same); and (3) a CRISPR/Cas transactivating noncoding RNA (trancRNA), a nucleic acid encoding the CRISPR/Cas trancRNA, and/or a modified host cell comprising the CRISPR/Cas trancRNA (and/or a nucleic acid encoding the same).

Abstract: Optoelectronic devices, such as photovoltaic devices, comprising a low band gap, solution processable diketopyrrolopyrrole or dithioketopyrrolopyrrole chromophore core or cores are disclosed. Also disclosed are methods of fabricating such optoelectronic devices.

Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.

Abstract: The present invention provides methods, systems and kits for performing microwell analysis in sealed small volumes. The microwells of the invention are sealed through the pairing of microwell and bead geometry wherein the diameter of the beads is greater than the diameter of the bottom of the microwells. Loading the beads into the microwells seals samples within an analytical space between the bottom of a nested bead and the bottom of the subject microwell.

Abstract: A sensor implanted in tissues and including a sensing layer is fabricated by mixing the signal transduction enzyme with non-reactive components including buffer salts and fillers, and spin coating the enzyme onto a substrate. The signal transduction enzyme is crosslinked by introducing the coated substrate in a vacuum chamber. In the chamber, a crosslinker evaporates and is deposited onto the enzyme, therefore crosslinking the enzyme.

Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.